Ventyx Biosciences (VTYX) Jefferies London Healthcare Conference 2024 summary

Pipeline and clinical development

• Advancing two compounds, VTX2735 (peripheral NLRP3) and VTX3232 (CNS-penetrant), into phase II trials in 2024.

• VTX3232 is being studied in early Parkinson’s patients, focusing on biomarker and imaging endpoints, with data expected in Q2 2025.

• A comprehensive obesity/cardiometabolic trial with VTX3232 will assess weight loss, metabolic, renal, and hepatic endpoints, including a combination arm with semaglutide.

• VTX2735 will be evaluated in recurrent pericarditis, with trial initiation by year-end and data anticipated in the second half of 2025.

• All trials are designed for robust proof-of-concept, with execution and timelines on track.

Preclinical and clinical data insights

• Preclinical mouse models show VTX3232 achieves 9–10% weight loss over 28 days, consistent across mono and combo studies.

• Human data for NLRP3 in obesity is lacking; expectations for weight loss in humans are modest compared to GLP-1s.

• Phase I data for VTX3232 demonstrated safety, tolerability, and significant knockdown of inflammatory biomarkers (hsCRP, IL-6, IL-1β) in both periphery and CSF.

• The obesity/cardiometabolic study will enroll patients with BMI 30–40 and elevated hsCRP, focusing on a range of metabolic and organ-specific endpoints.

• The study includes both monotherapy and combination (with semaglutide) arms, with data expected in early H2 2025.

Strategic outlook and future directions

• The obesity/cardiometabolic trial is structured to detect meaningful weight loss and metabolic improvements, with a focus on both monotherapy and add-on potential.

• If efficacy is modest, future directions may include combination or maintenance therapy with GLP-1s, or targeting specific cardiometabolic risk populations.

• The Parkinson’s trial will provide biomarker-driven proof-of-concept for CNS indications, with results guiding longer-term studies.

• The pericarditis trial offers a clear regulatory path if positive, leveraging an established mechanism and comparator.

• Execution remains a priority, with all programs advancing according to plan and key data readouts expected in 2025.